Information Provided By:
Fly News Breaks for March 5, 2020
MRNA
Mar 5, 2020 | 06:23 EDT
BofA analyst Geoff Meacham downgraded Moderna to Neutral from Buy with an unchanged $32 price target. The analyst is keeping his positive view on the company's core pipeline and platform, but contends that its year-to-date stock price run-up of 40.5% is driven by its mRNA-1273 efforts on coronavirus, which he does not expect to be de-risked for some time.
News For MRNA From the Last 2 Days
MRNA
Nov 23, 2020 | 09:54 EST
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Moderna (MRNA) initiated with an Equal Weight at Wells Fargo. 2. Biodesix (BDSX) initiated with a Buy at Canaccord. 3. MediaAlpha (MAX) initiated with an Outperform at William Blair. 4. G-III Apparel (GIII) initiated with a Neutral at UBS. 5. Leslie's (LESL) initiated with a Neutral at Goldman Sachs, Guggenheim and BofA and initiated with an Equal Weight at Morgan Stanley. The company was initiated with an Outperform at Telsey Advisory, Baird and William Blair as well. Additionally, Leslie's initiated with an Overweight at Piper Sandler. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.